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Host ICAMs play a role in cell invasion by
Mycobacterium tuberculosis and Plasmodium
falciparum
Kuhulika Bhalla1, Monika Chugh2,*, Sonali Mehrotra2,*, Sumit Rathore3, Sultan Tousif4, Ved Prakash Dwivedi4,
Prem Prakash1, Sachin Kumar Samuchiwal1, Sushil Kumar1, Dhiraj Kumar Singh1, Swapnil Ghanwat4,
Dhiraj Kumar4, Gobardhan Das4, Asif Mohmmed2, Pawan Malhotra2 & Anand Ranganathan1
Intercellular adhesion molecules (ICAMs) belong to the immunoglobulin superfamily and
participate in diverse cellular processes including host–pathogen interactions. ICAM-1 is
expressed on various cell types including macrophages, whereas ICAM-4 is restricted to red
blood cells. Here we report the identification of an 11-kDa synthetic protein, M5, that binds to
human ICAM-1 and ICAM-4, as shown by in vitro interaction studies, surface plasmon
resonance and immunolocalization. M5 greatly inhibits the invasion of macrophages
and erythrocytes by Mycobacterium tuberculosis and Plasmodium falciparum, respectively.
Pharmacological and siRNA-mediated inhibition of ICAM-1 expression also results in reduced
M. tuberculosis invasion of macrophages. ICAM-4 binds to P. falciparum merozoites, and the
addition of recombinant ICAM-4 to parasite cultures blocks invasion of erythrocytes by newly
released merozoites. Our results indicate that ICAM-1 and ICAM-4 play roles in host cell
invasion by M. tuberculosis and P. falciparum, respectively, either as receptors or as crucial
accessory molecules.
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A
ny discourse on the scenario of infectious diseases,
especially in the developing world, invariably includes
tuberculosis (TB) and malaria, reiterating their impact on
the current global public health situation. WHO (World Health
Organization) studies indicate almost 8.6 million new cases and
1.3 million TB deaths in 2012 (ref. 1). TB is caused by
Mycobacterium tuberculosis (Mtb) that primarily, although not
exclusively, invades lung phagocytic cells such as macrophages,
neutrophils, monocytes and dendritic cells (DCs). The incidence
of malaria is equally staggering, at 207 million cases, with 627,000
deaths reported by WHO for the year 2012 (ref. 2). One of the
main reasons for such high number of infections is the emergence
of resistance to the currently available drugs, as well as a severe
paucity of new drugs that can be added to the chemotherapy
regimen. Rifampicin and Artemisinin—recommended compo-
nents of first-line therapy against these diseases3,4—were
discovered in 1963 and 1973, respectively. There is thus an
urgent need to identify new drug targets and develop new drugs
against these pathogens.
Mtb and P. falciparum use multiple mechanisms to gain entry
into their respective host cells. Like many other bacteria, Mtb
utilizes complement receptors (CRs) and Toll-like receptors
(TLRs) for invading phagocytic cells. Other receptors involved in
Mtb internalization include mannose receptors5, surfactant
protein A (Sp-A) and Sp-A receptors6, CD14 (ref. 7), scavenger
receptors8 and DC-specific intercellular adhesion molecule
(ICAM)-3 grabbing nonintegrin9. More recent reports implicate
cell surface CCR5 in Mtb pathogenesis albeit not as a direct
receptor, but rather as a signal transducer involved in disease
progression10. Another study has identified mycobacterial cell
wall-associated Rv3083 as an agonist of TLR2 in order to activate
macrophages11. Despite the expanding knowledge of roles of such
potential receptors, there has been little success in using them to
develop new therapeutics or immune modulators for treating Mtb
infection.
In the context of malaria, the invasion of red blood cells
(RBCs) begins with an initial interaction of P. falciparum
merozoites with the RBC surface, followed by re-orientation that
allows the apical end of the merozoite to interact with the host
cell membrane. The RBC surface molecules currently character-
ized as receptors for this pathogen include members of the
glycophorin family12,13, CR1 (ref. 14), the recently identified
Basigin15 and Semaphorin 7A16. While receptor–ligand
interactions between glycophorin members and CR1 have been
characterized as ‘nonessential’ across many P. falciparum strains,
Basigin, thus far, is the only blood-group antigen that has been
validated as ‘essential’ for blood-stage growth of the parasite
irrespective of its resistance status15. As yet, for several known
parasite ligands, their receptors on RBC surface remain unknown.
ICAMs (ICAM-1 to ICAM-5) are members of the Ig super-
family and are structurally similar, consisting of varying number
of extracellular Ig domains stabilized by disulfide bonds, a
transmembrane region and a short cytoplasmic tail17. Most
ICAMs are expressed on a variety of cell types such as endothelial
and epithelial cells, lymphocytes, monocytes, eosinophils, and
ancestral haemopoietic cells—except ICAM-4 (Landstein–Weiner
blood-group antigen) that is found exclusively on RBCs.
Although the level of ICAM-4 expression on erythrocyte
surface decreases as they progress through various stages of
reticulocyte maturation, it is expressed to at least easily detectable
levels in mature erythrocytes18,19. Among the various ICAMs,
ICAM-1 (CD54) was the first to be described and studied
extensively20. ICAM-1 serves as a pathogen receptor for the
major group of Human Rhinoviruses21,22as well as for
Coxsackievirus VA21 (ref. 23). The progression of West Nile
virus across the blood brain barrier has also been attributed to an
increased expression of ICAM-1 (ref. 24). Ever since, the role of
ICAM-1 in the context of host–pathogen interactions continues
to be an area of active research. HIV-1, for example, acquires
integrins including LFA-1 during budding, and the integrin-
bound viral particles interact with ICAM-1 and show an
increased infectivity in nonsusceptible host cells25. In
P. falciparum infection, ICAM-1 and CD36 have been shown to
interact with infected erythrocytes and contribute to specific
pathologies of cerebral malaria26.
In the present study, using ‘codon-shuffled’ synthetic
libraries27,28, we identify an 84 amino-acid (aa)-long de novo
protein, M5, that binds both ICAM-1 and ICAM-4 potently.
Addition of M5 during Mtb infection of THP-1 cells as well as
murine peritoneal macrophages reduce Mtb invasion significantly.
The use of a known ICAM-1 expression inhibitor, and ICAM-1
silencing by short interfering RNA (siRNA), results in a drastic
reduction in Mtb infection, confirming the role of ICAM-1 during
the infection process. We also determine the effect of M5 on the P.
falciparum invasion of human RBCs. Addition of M5 significantly
blocks P. falciparum invasion, uniformly across drug-susceptible
(3D7) and drug-resistant parasite strains (Dd2, HB3 and
MCamp). Together, these results are indicative of a receptor-like
role of ICAMs for host cell invasion by two important intracellular
pathogens, Mtb and P. falciparum, and also unveil alternative drug
targets for the development of new inhibitors based on the
interactions reported here.
Results
ICAM-1 is involved in Mtb host–pathogen interactions. To
identify novel host factors involved in Mtb invasion of human
cells, a library-based protein–protein interaction analysis was
performed using the Bacteriomatch two-hybrid system. An Mtb
H37Rv genomic DNA library cloned in pBTnn vector29, a
modified plasmid from the two-hybrid pBT vector, was screened
with a human lung cDNA library cloned in the pTRG vector, to
find interacting partners. On the basis of a blue–white selection,
two colonies positive for interaction(s) were selected and
sequenced. Blast analysis identified that both pairs of
interacting partners had a 271-aa-long fragment of ICAM-1
that comprises a portion of the extracellular region (D3D5
domains), transmembrane region as well as the cytoplasmic tail
(hereafter referred to as ICAM-1271) in pTRG and two different
mycobacterial metabolic proteins: a 128-aa-long C-terminal
region of acetolactate synthase (large subunit), IlvB2 and an
83-aa-long C-terminal region of 3-hydroxybutyryl-CoA
dehydrogenase, a known secretory protein (Rv1715 and fadB3;
Fig. 1a) in pBTnn. The sequences were analysed with NCBI
BLAST and their theoretical protein parameters were computed
using the ExPASy ProtParam tool (Fig. 1b). Sequences of the
proteins are provided in Supplementary Figs 1a,b and 2. The
interactions were confirmed over repeated rounds of re-
transformation and segregation of plasmids.
M5 binds ICAM-1 and disrupts its dimerization. Since ICAM-1
was identified as a possible host factor involved in Mtb host–
pathogen interactions, we next screened a dicodon polypeptide
synthetic library to identify potential de novo peptide/protein
binders to ICAM-1271. Two-hybrid screening was performed with
ICAM-1271 cloned into pTRGnn plasmid and a dicodon shuffled
polypeptide library cloned in pBTnn. A de novo, 84-aa-long
protein, named M5 (Fig. 1d, left) was identified after several
rounds of segregation, re-cloning and re-transformations.
We further tested the M5 interaction with different domains
of ICAM-1: extracellular (ICAM-1EC), transmembrane
(ICAM-1TMþCyto) and cytoplasmic (ICAM-1Cyto) based on the
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structural information available for ICAM-1 (refs 30,31) (Fig. 1c,d,
right). As shown in Fig. 1c (left), interaction was observed
between M5 and ICAM-1271 as well as with ICAM-1EC. However,
no such interaction was observed between M5 and ICAM-1Cyto.
The strengths of these interactions were further corroborated by
quantitative liquid b-galactosidase enzyme assays (Fig. 1c, right).
The well-studied interaction between two mycobacterial proteins,
CFP10 and ESAT6, was used as a positive control32.
On host leukocytes, ICAM-1 predominantly exists as a dimer,
and it is in this form that it binds its natural ligands like
LFA-1 and Mac-1. To study whether the bacterially expressed
ICAM-1271 or its fragments also exhibit dimerization, genes
corresponding to ICAM-1271 or its fragments were cloned into
both pTRGnn and pBTnn vectors and interaction studies
performed. ICAM-1271/ICAM-1271 and ICAM-1EC/ICAM-1EC
pairs showed significant interactions, while ICAM-1TMþCyto/
ICAM-1TMþCyto displayed it to a lesser extent (Fig. 2a, left). The
dimeric interactions were subsequently quantified via a liquid
b-galactosidase enzyme assay (Fig. 2a, right). We next evaluated
the effect of M5 on ICAM-1 dimerization using a bacterial three-
hybrid system developed previously by us33. The system allowed
us to transform the ‘blue’ two-hybrid R1 reporter strain carrying
ICAM-1271pTRGnn and ICAM-1271pBTnn vectors, with a third
compatible plasmid pMTSA-expressing M5 protein. The gene
cloned in pMTSA vector was under the tight regulation of the
arabinose-inducible pBAD promoter and the triple transformant
clones were plated on X-gal indicator plates with and without
L-arabinose. Expression of M5 in the presence of L-arabinose
turned the ICAM-1271/ICAM-1271-expressing strain from blue to
white, indicating that ICAM-1 dimerization was disrupted by M5
(Fig. 2b). Expression of the reporter lacZ was monitored over
incremental L-arabinose concentrations (Fig. 2c, left), and the
increase in M5 induction (Fig. 2c, right) corresponded with
declining reporter enzyme activity confirming the disruption.
M5 interacts with ICAMs. Protein–protein interactions between
M5 and ICAM-1 or ICAM-4 were evaluated using recombinant
proteins. Recombinant ICAM-1 and ICAM-4 were acquired
commercially from Sino Biological Inc., China. His-tagged M5
(M5-His) was purified from E. coli BL21 (DE3) strain under
denaturing conditions, and the 11-kDa M5 protein dialysed
against decreasing concentrations of denaturant (Fig. 3a). Because
M5 has no homology to any known protein, we deciphered its
secondary structural elements by circular dichroism (CD) spec-
troscopy. The CD spectra of the protein at varying concentrations
l. Bacterial two-hybrid between
human lung cDNA library and
Mtb genomic DNA library
ICA
M-
12
71 /I
IvB
2
ICA
M-
12
71 /
pB
Tn
n(–
)
ICAM-1 271/fadB3
CFP10/ESAT6(+)
ICA
M-1
271
ICA
M-1
Cyt
o
IC
AM
-1
EC
/
pB
Tn
n(–
)
ICAM-1 EC
ICAM
-1 TM
+CytoCFP10/
ESAT6(+)
NAME
M5 sequence
Characteristics
Amino acids — 84
M.W.—10.04
pl — 5.16
GRAVY — (–0.117)
MGYSGRHVFKMHQLDIDIQLDIDIDI
MHMHQLDIRTDIDIDIQLDIMHDIRT
MHMHDIRTDIDIDIMHMHDIRTELFK
HVAAAV
ICAM-1271
Mtb1 (IIvB2)§
Mtb2 (fadB3)¶
Amino acids
271 29.637
12.942
8.778
Co
-tr
a
n
sf
o
rm
a
n
ts
8.64 7
4
Nil
–0.356
–0.393
–0.223
ICAM-1271 pTRGnn versus M5 pBTnn
ICAM-1EC pTRGnn versus M5 pBTnn
ICAM-1TM+Cyto pTRGnn versus M5 pBTnn
ICAM-1Cyto pTRGnn versus M5 pBTnn
CFP10 pTRGnn versus ESAT6 pBTnn
ICAM-1EC pTRGnn versus pBTnn
6.33
5.88
Relative miller units
0 25
ICAM-1
ICAM-1EC
ICAM-1271
D1
D2
D3
D3
D3
D4
D4
D5
216 aa
ICAM-1TM+Cyto
ICAM-1Cyto
D4
D5
Cyto
532 aa 271 aa 55 aa 28 aa
Cyto Cyto
TM TM TM
D5
50 75
***
****
**
100
128
83
M.W. pl
III. Bacterial two-hybrid
between ICAM-1271 and
dicodon libraries 
IV. Identification of ICAM-1271
binder ‘M5’ from dicodon library
II.  Host–pathogen interacting
partners -
human ICAM-1271 and
Mtb fadB3/IIvB2 identified
No. of cysteines GRAVY
i
i
ii
ii
Figure 1 | Identification of de novo protein binder to ICAM-1. (a) X-gal indicator plate of bacterial two-hybrid experiment between human lung cDNA and
Mtb genomic DNA libraries. All streaks are labelled to represent genes cloned in pTRG/pBTnn. ICAM-1271pTRG/empty pBTnn is the negative control;
CFP10pTRGnn/ESAT6pBTnn is the positive control. (b) Protein parameters highlighting length, molecular weight (MW), isoelectric point (pI), number of
cysteines and grand average of hydropathicity (GRAVY) of the identified host–pathogen protein interactors. Sequences of the identified proteins are
provided in Supplementary Figs 1 and 2. (c) Bacterial two-hybrid assay to identify de novo protein/peptide binder to ICAM-1271 and its domains. (i) X-gal
indicator plate. All streaks are labelled to represent genes cloned in pTRGnn/pBTnn. (ii) Liquid b-galactosidase assay to measure relative enzyme activity
(M.U.) of co-transformant pairs. Relative Miller units: ICAM-1271pTRGnn versus M5pBTnn (60.49±4.255); ICAM-1ECpTRGnn versus M5pBTnn
(39.02±1.583); ICAM-1TMþCytopTRGnn versus M5pBTnn (18.71±4.855); ICAM-1CytopTRGnn versus M5pBTnn (14.70±2.176); positive control—
CFP10pTRGnn versus ESAT6pBTnn (86.10±6.949); negative control—ICAM-1ECpTRGnn versus empty pBTnn (2.779±1.014). The graph is the average of
three independent assays and s.d. is represented by error bars. All values were tested for significance using a two-tailed unpaired Student’s t-test with
Welch’s correction. **Po0.01, ***Po0.001, ****Po0.0001. (d) (i) Amino-acid sequence of the identified de novoM5 polypeptide. Protparam tool from the
ExPASy server (http://web.expasy.org/protparam/) was used to ascertain MW, pI and hydrophobicity of M5. (ii) Schematic showing a comparison
of full-length ICAM-1 transmembrane protein (532 amino acids) with ICAM-1271 and its various fragments: ICAM-1271 (271 amino acids), ICAM-1EC
(216 amino acids), ICAM-1TMþCyto (55 amino acids) and ICAM-1Cyto (28 amino acids). yIlvB2—N-terminal putative acetolactate synthase large subunit;
zfadB3—C-terminal 3-hydroxybutyryl-CoA dehydrogenase; EC—extracellular; TMþCyto—transmembraneþ cytoplasmic tail; Cyto—cytoplasmic tail.
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were analysed using the K2D3 server (http://k2d3.ogic.ca)34
and found to show B50% b-sheet and B4% a-helical folds
(Supplementary Fig. 3b–d).
An in vitro pull-down assay was performed to confirm the
interaction between M5 and recombinant ICAM-1. For the
interaction analysis, M5-His and a nonspecific histidine-tagged
protein Actin-related protein 2/3 subunit 4 (ARPC4, a 22-kDa
subunit of the human Arp2/3 protein complex) were immobilized
separately on Ni-NTA resin. Recombinant ICAM-1 protein was
incubated with M5 or ARPC4-bound resins and the bound
proteins eluted subsequently by boiling the resin with 5 SDS-
loading dye. The eluted fractions were analysed by SDS–PAGE
and M5-bound Ni-NTA resin was able to retain ICAM-1
(Fig. 3b), while the nonspecific protein ARPC4 immobilized on
the Ni-NTA column failed to bind ICAM-1.
The interactions between M5 and recombinant full-length
ICAM-1 or ICAM-4 were also confirmed by reciprocal
ELISA-based interaction assays. Unlike ICAM-1, which is
constitutively expressed on a variety of cell types, ICAM-4 is
expressed exclusively on RBC surface. The homology between
ICAM-1 and ICAM-4 Ig-like domains is 440–50% (www.ebi.ac.
uk/Tools/msa/clustalo/; Supplementary Fig. 4a,b). For the assay,
M5, ICAM-1 or ICAM-4 proteins were immobilized in ELISA
plates and the wells overlaid with the corresponding interacting
proteins. After rigorous washing, antibodies against the overlaid
proteins were used to detect successful binding. The binding of
M5 with ICAM-1 or ICAM-4 was found to be concentration-
dependent. A set of wells coated with ICAM-1 and ICAM-4 were
also incubated with polyclonal anti-ICAM-1 and anti-ICAM-4
antibodies, respectively, to investigate whether the antibodies
would perturb/mask ICAM/M5 interactions (Fig. 3c). Binding
between ICAMs and M5 was similar to control proteins detected
by their specific antibodies (anti-His, anti-ICAM-1 or anti-
ICAM-4). These were also specific as neither ICAM-1 nor ICAM-
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Figure 2 | Disruption of ICAM-1271 dimerization by M5. (a) Bacterial two-hybrid assay to assess structural fidelity of ICAM-1271 and its domains. (i) X-gal
indicator plate. All streaks are labelled to represent genes cloned in pTRGnn/pBTnn. (ii) Liquid b-galactosidase assay to measure relative enzyme activity
(M.U.) of co-transformant pairs: ICAM-1271pTRGnn versus ICAM-1271pBTnn (75.16±1.519); ICAM-1ECpTRGnn versus ICAM-1ECpBTnn (61.28±6.111);
ICAM-1TMþCytopTRGnn versus ICAM-1TMþCytopBTnn (45.45±3.041); ICAM-1CytopTRGnn versus ICAM-1CytopBTnn (10.77±5.195); positive control—
CFP10pTRGnn versus ESAT6pBTnn (92.19±4.195); negative control—ICAM-1ECpTRGnn versus empty pBTnn (2.249±1.189). The graph is the average of
three independent assays and s.d. is represented by error bars. All values were tested for significance using a two-tailed unpaired t-test with Welch’s
correction. **Po0.01, ****Po0.0001. (b) Bacterial three-hybrid X-Gal indicator plate (i) without L-Arabinose and (ii) with L-Arabinose. Test streaks: triple
co-transformant containing ICAM-1271pTRGnn, ICAM-1271pBTnn and M5pMTSA; control streaks: triple co-transformant containing ICAM-1271pTRGnn,
ICAM-1271pBTnn and empty pMTSA. (c) L-Arabinose gradient liquid b-galactosidase assay. (i) Relative b-galactosidase activity (M.U.) of the triple co-
transformants ICAM-1271pTRGnn/ICAM-1271pBTnn versus empty pMTSA (red line) and ICAM-1271pTRGnn/ICAM-1271pBTnn versus M5pMTSA (black
line), is plotted against a range of L-Arabinose concentrations. The graph is the average of three independent assays and s.d. is represented as error bars.
Multiple unpaired t-tests to compare enzyme activity of each triple co-transformant across individual L-Arabinose concentrations were used. Statistical
significance was determined using the Holm–Sidak method, and *Po0.05 was considered significant. (ii) Western blot (see Supplementary Fig. 3a) of E.
coli whole-cell lysates to analyse the expression of M5 protein induction with increasing concentrations (corresponding to the concentrations displayed on
x axis of the graph) of L-arabinose.
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4 interacted with a nonspecific His-tagged protein ARPC4. The
controls for the ELISA-based interaction assay are shown in
Supplementary Fig. 4c.
The M5/ICAM-4 interaction was further studied using surface
plasmon resonance (SPR). Using this approach, we found
that M5 displayed a strong interaction with ICAM-4 with
an equilibrium dissociation constant (KD)E10.07±0.02 nM
(Fig. 3d) and an RmaxE49.95±0.23 response unit. The KD
and Rmax were derived using a nonlinear curve-fitting algorithm,
calculated based on a one-site-specific binding model (1:1
interaction) using the equation Y¼RmaxX/(KDþX), where
Y is the SPR equilibrium resonance unit value (Req) and X is the
concentration of the injected analyte. A good curve-fit with R2
equal to 0.9999 was observed using the described parameters.
The potent ability of M5 to bind ICAM-1 and ICAM-4
prompted us to evaluate its potential as a modulator of ICAMs,
and thereby also assess their role in Mtb and P. falciparum
invasion of host cells.
ICAM-1 is crucial for M. tuberculosis infection. Before inves-
tigating whether M5/ICAM-1 interaction had any modulatory
effect on Mtb infection, it was prudent to assess whether M5
localized to the ICAM-1 sites on the macrophage cell surface.
A localization experiment was performed wherein untreated,
anti-ICAM-1 pAb-treated and A205804—a commercial small
molecule-selective inhibitor of cellular ICAM-1 expression35—
treated THP-1 macrophages were incubated with M5, followed by
the addition of the cross-linker dimethyl suberimidate. Anti-His,
anti-ICAM-1 monoclonal antibody (mAb) and fluorochrome-
conjugated secondary antibodies, namely, Alexa Fluor 594 and
Alexa Fluor 488, were used for detection of M5 and ICAM-1,
respectively (Fig. 4a, control). Considerable co-localization
between M5 and ICAM-1 on untreated THP-1 macrophages
was found (Pearson’s coefficient 0.78). Remarkably, A205804-
treated macrophages did not stain positive for M5-His on cell
surface (Fig. 4a, A205804-treated), suggesting that the interaction
between ICAM-1 and M5 is specific. Anti-ICAM-1 pAb, however,
failed to mask ICAM-1 and abrogate M5 binding to the cell
surface (Fig. 4a, antibody-treated).
To evaluate the role of ICAM-1 in the uptake of Mtb, phorbol
12-myristate 13-acetate (PMA)-activated THP-1 cells were
incubated with M5 at varying concentrations (0–25 mM). In
control experiments, a similar number of THP-1 macrophages
were treated with buffer solution without any protein/polypeptide
as well as with a nonspecific protein ARPC4. The treated cells
were infected with Mtb H37Rv-GFP (green fluorescent protein)36
and infection was monitored by detecting GFP fluorescence
through flow cytometry. The treated cells were also analysed for
the expression of ICAM-1 by using Alexa Fluor 647-conjugated
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Figure 3 | In vitro protein–protein interaction between M5 and ICAMs. (a) Purification of M5-His under denaturing conditions on a Ni-NTA column.
Coomassie-stained 10% Tris-Tricine polyacrylamide gel. Western blot of purified M5-His using anti-His antibody. Lane M: Pre-stained protein marker;
Lane 2: purified C-terminal His-tagged M5 protein (11.105 kDa). (b) In vitro pull-down assay of purified ICAM-1 using M5-His-bound Ni-NTA resin.
Coomassie -stained 15% SDS–PAGE. Controls—ARPC4 (nonspecific his-tagged protein; 21.45 kDa); M5-His (11.105 kDa); recombinant ICAM-1 (B90 kDa)
are indicated with arrows. Lane M: pre-stained protein marker; Ni-NTA resin pull-down lanes—ICAM-1 pull downs with: M5-His; ARPC4; unbound Ni-NTA
resin. (c) ELISA-based analysis of interaction between M5 and ICAM-1 or ICAM-4. M5, ICAM-1 and ICAM-4 were coated at concentrations of 5, 15, 25 and
50 nM. In a subset of wells, ICAM-1- and ICAM-4-coated wells were incubated with anti-ICAM-1 or anti-ICAM-4 antibody, respectively. The overlaid
interacting protein is indicated within the parentheses in the graph legend. Subset in which a polyclonal antibody was added before M5 is indicated in the
legend. Absorbance by control proteins is shown in Supplementary Fig. 4c. The ELISA for all interactions was performed in triplicates. Histograms of the
mean absorbance at 450nm with s.d. are plotted for each concentration. (d) Kinetic analysis of M5 and human ICAM-4 interaction. Nonlinear regression
curve fit for Req plotted against injected ICAM-4 concentrations. The ka and kd of the interaction were 9.96 104 and 1 10 3M, respectively; the
derived KD¼ 10.07±0.02 nM and Rmax¼49.95±0.23. The inset shows the SPR sensograms of injected ICAM-4 at 20ml min over immobilized M5 in a
CM5 sensor chip. The Req for each concentration was calculated after analysis of the association and dissociation from a 1:1 binding model (black lines).
The analyte concentration for each sensogram is indicated.
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anti-ICAM-1 antibody. M5-treated cells showed a significant
decrease in Mtb infection compared with ARPC4- or buffer-
treated THP-1 cells (Fig. 4b and Supplementary Fig. 5). All
samples, including those treated with M5, showed a comparable
expression level of cell surface ICAM-1 (Fig. 4c and
Supplementary Fig. 5). The experiment was performed in
triplicates, and was reproducible across each individual
repetition. To rule out the possibility that the decrease in Mtb
infection in M5-treated cells was because of cell death caused by
the protein itself, a viability assay was performed. Treated and
untreated THP-1 macrophages were stained with 7AAD, followed
by flow cytometry analysis. No change in the cell viability was
observed in the M5-treated cells (Supplementary Fig. 6).
To study the importance of ICAM-1 in Mtb infection, THP-1
cells were treated with A205804. The reported IC50 of A205804
for selective inhibition of ICAM-1 is 25 nM37. THP-1
macrophages treated with suboptimal (20 nM) and optimal
(50 nM) of A205804 were analysed for H37Rv-GFP infection
and ICAM-1 expression. The results showed a drastic decrease
in Mtb infection in A205804 (50 nM)-treated cells and a
concomitant significant drop in ICAM-1 expression (Fig. 5a,b
and Supplementary Fig. 8a,b). Together, these results suggested a
role of ICAM-1 in Mtb infection of mammalian cells.
To extend the results established in THP-1 macrophages, a
similar experiment was performed with murine peritoneal
macrophages. BALB/c mice were administered peritoneal injec-
tions of thioglycollate. Macrophages from the killed mice were
harvested by peritoneal lavage and were enriched overnight to
facilitate binding of activated macrophages to assay plates.
Following enrichment, the cells were treated with varying
concentrations of M5 or A205804 before Mtb H37Rv-GFP
infection. We found a dose-dependent reduction in percentages
of Mtb-infected macrophages with increasing concentrations of
M5 (0–25 mM; Fig. 4d and Supplementary Fig. 7). All samples
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Figure 4 | Role of ICAM-1 in Mtb infection of activated THP-1 cells. (a) Co-localization of M5-His to sites of ICAM-1 expression on the THP-1 surface.
Activated THP-1 cells were incubated with 25mM M5-His (control) for 1 h and 50 nM A205804 (A205804-treated) or polyclonal anti-ICAM-1 antibody
(antibody-treated) for 24 h. A205804- and antibody-treated samples were further incubated with M5-His for 1 h. Co-localization was detected with
anti-his and anti-ICAM-1 antibodies. The cells were stained with fluorochrome-conjugated secondary bodies against His-tag (red), ICAM-1 (green)
and counterstained with DAPI. Analysis of the co-localization threshold scatter (488 versus 594 nm) was used to determine Pearson’s coefficients:
control—0.78, Ab-treated—0.64. Scale bar 20mm. (b) Bar graph showing the percentages of H37Rv-GFP-infected CD54þ THP-1 macrophages when
treated with increasing concentrations of M5 protein (0–25mM). The data are representative of three independent experiments. Untreated THP-1
macrophages infected with H37Rv-GFP were considered as the positive control against which inhibition of infection was compared for significance.
Differences in infection were calculated using unpaired t-tests with Welch’s correction. *Po0.01, **Po0.001. (c) ICAM-1 expression level of untreated and
M5-treated THP-1 macrophages using anti-ICAM-1 antibody following infection. The data are represented as fold change in the MFI. The dot plots with
gated populations are shown in Supplementary Fig. 5. (d) Percentages of H37Rv-GFP-infected murine peritoneal macrophages when treated with increasing
concentrations of M5 protein (0–25mM). Untreated peritoneal macrophages infected with H37Rv-GFP were considered as the positive control against
which inhibition in infection was compared for significance. The data are representative of three independent experiments. Differences in infection were
calculated using unpaired t-tests with Welch’s correction. **Po0.001. (e) ICAM-1 expression level of untreated, M5-treated or A205804-treated
macrophages using anti-ICAM-1 antibody following infection. The data are represented as fold change in the MFI. Differences in ICAM-1 expression were
calculated using unpaired t-tests with Welch’s correction. **Po0.001. The dot plots with gated populations are shown in Supplementary Fig. 7a,b.
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displayed comparable ICAM-1 expression, with the exception of
A205804-treated (50 nM) macrophages (Fig. 4e).
Finally, in an effort to establish the proof-of-concept that
ICAM-1 is indeed crucial for Mtb invasion, and could therefore
serve as a potential drug target, ICAM-1 expression in THP-1
macrophages was knocked down by siRNA directed against
ICAM-1. A series of transfection experiments were set up varying
the ratio of transfection agent versus siRNA, and silencing was
monitored using western blots and flow cytometry. Maximum
silencing was achieved with 60 nM of siRNA pool (Silencer Select,
Ambion) at 72 h (Fig. 5c and Supplementary Fig. 9a,b). Wild-
type, control siRNA (scrambled) and siRNA-transfected THP-1
macrophages were infected with Mtb H37Rv-GFP. We found as
much as 70% reduction in infection in the specific siRNA-
transfected THP-1 subset (Fig. 5d and Supplementary Fig. 9c),
while THP-1 macrophages transfected with scrambled siRNA or
with transfection reagent alone did now show any reduction in
H37Rv-GFP infection.
ICAM-4 essential for P. falciparum invasion of erythrocytes.
Among the many ICAMs identified thus far, ICAM-4 remains an
erythrocyte-specific adhesion molecule. Before evaluating the
effect of M5 in the invasion of merozoites, we assessed whether
M5 binds to ICAM-4 expressed on RBC surface (Supplementary
Fig. 10a). Co-localization of M5 to the sites of ICAM-4 expression
on the RBC surface was performed using anti-His antibody for
the detection of M5 and polyclonal anti-ICAM-4 antibody (clone
C-20) to probe ICAM-4 on RBC surface. Results showed con-
siderable expression of ICAM-4 on the RBC surface and a robust
co-localization (Pearson’s coefficient 0.7) with M5 (Fig. 6a). As
with ICAM-1 in case of THP-1 macrophages, polyclonal anti-
ICAM-4 antibody was also unable to mask the interaction
between M5 and ICAM-4 on RBCs (Supplementary Fig. 10b). On
the basis of these observations, in vitro P. falciparum invasion
inhibition assays were performed. Purified mature schizont stage
parasites (3D7 strain) were incubated with varying concentrations
(7.5–25 mM) of M5 protein. Parasitaemia in control and treated
cultures was estimated after 24 h using flow cytometry. A dose-
dependent decrease in parasitaemia was observed in M5-treated
cultures, with a maximum of B80% decrease in parasitaemia
observed in cultures treated with 25 mM of M5 when compared
with untreated cultures (Fig. 6b). The result was reproducible
over three independent experiments each carried out in duplicate.
A similar dose-dependent decrease in parasitaemia was witnessed
with three other strains of P. falciparum: Dd2, MCamp (sialic
acid-dependent strains) and HB3 (sialic acid-independent strain)
upon treatment with M5 (Fig. 6b). Further, we assessed the ability
of M5 to inhibit invasion in neuraminidase-treated RBCs,
as neuraminidase treatment blocks the invasion in sialic
acid-dependent strains. Similar level of invasion inhibition was
observed in the presence of M5 protein in neuraminidase-treated
or -untreated RBCs (Supplementary Fig. 10c). Microscopic
analysis of Giemsa- and 40,6-diamidino-2-phenylindole (DAPI)-
stained culture smears showed that, while new rings were
observed in control cultures, M5-treated cultures showed a
significantly lesser number of new rings and higher number of
free and attached merozoites to RBCs (Fig. 6c, Supplementary
Fig. 10d).
To evaluate the viability of M5-treated parasites, a wash-off
experiment was carried out wherein purified mature schizonts
(44 h post infection (hpi)) were incubated with RBCs either in
presence or absence of M5. The schizonts were allowed to rupture
and merozoites allowed to invade new RBCs to form ring-stage
parasites. In the M5-treated set there was a threefold reduction in
RBC invasion by merozoites compared with control. Following
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Figure 5 | ICAM-1 is important for Mtb infection. (a) Percentages of H37Rv-GFP-infected THP-1 cells when treated with suboptimal (20nM) and optimal
(IC50 50nM) A205804. (b) ICAM-1 (CD54) expression level for A205804-treated THP-1 cells. The data are represented as fold change in MFI. Flow cytometry
plots for these data are shown in Supplementary Fig. 8a,b. Differences in infection or ICAM-1 expression were calculated using unpaired t-tests with Welch’s
correction. **Po0.005, ****Po0.0001. (c) ICAM-1 expression in THP-1 macrophages following silencing with 60nM ICAM-1 siRNA, at 48 and 72h. Scrambled
version of ICAM-1 siRNA was used to validate silencing. The data are represented as fold change in MFI. Flow cytometry dot plots and western blot for
ICAM-1 expression is provided in Supplementary Fig. 9a,b. (d) Comparison in percentages of H37Rv-GFP-infected wild-type (WT), scrambled and siRNA-treated
THP-1 macrophages. Flow cytometry plots for these data are shown in Supplementary Fig. 9c. All data sets were acquired over three independent experiments.
Statistically significant differences in infection were calculated using unpaired t-tests using Welch’s correction. *Po0.05, ns¼ not statistically significant.
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initial invasion, M5 was washed off from the cultures and the
parasite growth monitored for the next three cycles. There was no
difference in the fold change in parasitaemia in control and M5-
treated sets in subsequent cycles (Supplementary Fig. 10e). To
rule out any inhibitory effect of M5 on parasite development, we
also assessed parasite growth across asexual stages in presence of
M5 protein; the result showed that M5 has no effect on parasite
developmental stages (Supplementary Fig. 10f). Together, these
results suggested that the decrease in parasitaemia observed in
M5-treated cultures was because of invasion inhibition and not
because of loss of viability of the parasites or any other inhibitory
effect of M5 on different stages of parasite development.
To establish whether P. falciparum merozoites bind directly
to ICAM-4, recombinant ICAM-4 was added to in vitro
P. falciparum cultures and the binding detected using anti-
ICAM-4 antibody. As shown in Fig. 6d, significant binding of
ICAM-4 on the merozoite surface was observed. These results
suggest that merozoites express ligand(s) that bind to ICAM-4
present on the RBC surface. Following this, recombinant ICAM-4
(175 nM) was added to the merozoite invasion assay mix and new
ring formation monitored. The addition of recombinant ICAM-4
to parasite cultures blocked the invasion of newly released
merozoites and in-turn reduced development of ring-stage
parasites by 80% when compared with control-untreated cultures
(Fig. 6e). Together, these results implicate ICAM-4 in the
invasion of P. falciparum merozoite into RBCs.
Discussion
ICAM-1 has been classified as a type I transmembrane protein
with an extracellular region consisting of 453 amino acids,
arranged in the form of five Ig-like domains. ICAM-4, on the
other hand, is a relatively small molecule that comprises two
Ig-like extracellular domains and is expressed exclusively on RBC
surface. Without exception, all ICAMs bind to CD11a/CD18
(LFA-1, aLb2) on leukocytes. ICAM-1, ICAM-2 and ICAM-4 also
interact with the granulocyte/monocyte-enriched b2 integrin
CD11b/CD18 (Mac-1, aMb2)38–40. ICAM-4 is unique in that it
is the only Ig superfamily member that has also been shown to
bind to CD11c/CD18, av integrins (avb1, avb3 and avb5) on
nonhaemopoietic cells, a4b1 on haemopoietic cells and aIIbb3 on
platelets41–43. However, the role of ICAMs in the invasion by two
important intracellular pathogens, Mtb and P. falciparum, was
hitherto unknown. While no direct evidence connecting Mtb
invasion of host cells and ICAM-1 has thus far come to light,
there are studies that show an increase in the expression levels of
ICAM-1 on macrophages infected with Mtb44. In addition, even
though this change in expression could be ascribed as a response
of the immune system to recruit more leukocytes to the site of
bacterial infection, the increase is so abnormally high45 that we
speculate it to be a pathogen-specific response.
In the present study, while screening for host-interacting
molecules of Mtb using a human cDNA library, ICAM-1
was identified as the host counterpart involved in separate
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Figure 6 | Erythrocytic ICAM-4 is involved in merozoite invasion. (a) Co-localization of M5-His to sites of ICAM-4 expression on the RBC surface.
Human erythrocytes were incubated with 25mM recombinant M5-His for 30min followed by incubation with anti-His and anti-ICAM-4 antibodies. The
cells were stained with fluorochrome-conjugated secondary antibodies against His-tag (green) and ICAM-4 (red) followed by confocal microscopy. In a
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(these co-localization results are provided in Supplementary Fig. 10b) Scale bar 2 mm. (b) Invasion inhibition of P. falciparum strains 3D7, Dd2, HB3 and
MCamp by M5. Purified recombinant M5 protein (7.5–25mM) was added to mature schizont stage parasite culture and the parasitaemia estimated after
24 h using flow cytometry. The data represent an average of three independent experiments each performed in duplicate. Invasion observed in control
culture was taken as 100%. The M5 buffer components did not affect parasite invasion. (c) Giemsa-stained smears of parasite culture treated with M5 at
the schizont stage. While new rings were observed in untreated culture (M5( )), considerable number of free merozoites and merozoites attached to the
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bars represent s.d. (d) Binding of ICAM-4 on the merozoite surface. (i) Merozoites were incubated with recombinant ICAM-4 protein (175 nM) followed by
staining with anti-ICAM-4 antibody and DAPI. (ii) Merozoite in the absence of ICAM-4. (e) Recombinant ICAM-4 protein blocks invasion of human
erythrocytes by merozoites. Percoll-purified schizont stage P. falciparum culture was treated with purified ICAM-4 protein. New ring formation was
estimated after 15 h using Giemsa-stained smears. Approximately 80% drop in ring formation was observed in ICAM-4-treated culture.
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interactions with C-terminal regions of two mycobacterial
metabolic proteins IlvB2 and fadB3 (Rv1715). While there is
little literature available on IlvB2, fadB3 has been characterized
as a secretory, nonessential protein46 involved in fatty acid
metabolism. In the past two decades bacterial metabolic enzymes
have begun to be recognized for their moonlighting capabilities
and as determinants of virulence. This has been previously
reviewed in detail, with many such proteins now known for
Mtb47. Interaction with host ICAM-1 indicates possible
moonlighting functions of IlvB2 and fadB3 and will require
further investigation.
To investigate whether host ICAM-1 does indeed play a role in
Mtb infection, we screened ICAM-1 against a synthetic polypep-
tide library and identified an 84-amino-acid-long M5 protein that
bound ICAM-1 with high affinity. We have previously used a
similar approach to identify synthetic proteins that bind and
inhibit crucial enzymes of Mtb29. Since ICAM-1 possesses
extracellular Ig-like domains, a transmembrane domain and a
cytoplasmic domain, a bacterial two-hybrid-based analysis was
performed with M5 as a bait, with different domains of ICAMs;
ICAM-1271, ICAM-1EC, ICAM-1TMþCyto and ICAM-1Cyto as
ligands. The analysis showed that M5 binds primarily to the
extracellular domains of ICAM-1 and that this binding also
prevents the dimerization of ICAM-1. Interaction between M5
and ICAM-1 was further confirmed using ELISA, co-localization
as well as by pull-down assays. Interestingly, SPR experiments
also revealed M5 to interact with ICAM-4 with a high affinity,
characterized by KDE10.07 nM. Surprisingly, addition of anti-
ICAM pAbs in the M5-ICAM-binding reactions did not seem to
diminish M5’s ability to bind ICAM-1 or ICAM-4. This may
possibly be because the antibody-binding epitope(s) are distinct
from the M5-binding domain. Most notably, a study by
Bartholdson et al.48 also reported that the P. falciparum protein
MTRAP (expressed on merozoites and involved in motility and
invasion) is a ligand to Semaphorin-7A on RBCs and showed that
anti-MTRAP mAb and anti-Semaphorin-7A monoclonal and
polyclonal antibodies were unable to block merozoite invasion
into RBCs. Having identified a potent ICAM-binding synthetic
polypeptide, we next assessed the role of ICAMs in the context of
two pathogens, M. tuberculosis and P. falciparum, in host cell
invasion.
It is well known that Mtb infects alveolar macrophages through
a series of events that ultimately determine whether the bacilli is
able to evade the innate immune response and successfully
survive intracellularly49. The uptake itself engages a myriad
of phagocytic receptors, thereby initiating specific signalling
pathways and modulating several immunobiological processes
during and after phagocytosis50. Once we identified host ICAM-1
to be possibly implicated in host–pathogen interactions, the effect
of M5 on Mtb invasion of macrophages was analysed. The results
showed 470% inhibition in Mtb invasion, consistently across
THP-1 as well as murine peritoneal macrophages, thereby
suggesting the role of ICAM-1 in Mtb entry into the
macrophages. To further confirm the role of ICAM-1 as an
Mtb receptor, ICAM-1 expression on THP-1 macrophages was
blocked by the addition of A205804—whose use as an ICAM-1
expression inhibitor has been described earlier35—as well as
PMA-activated THP-1 cells using siRNAs. H37Rv infection was
inhibited in these treated cells by as much as 70% compared with
wild-type and control siRNA-transfected macrophages. Together,
the results show that M5 binds ICAM-1 extracellularly, but bears
no effect on the host cell ICAM-1 expression. There are previous
reports of disruption of the ICAM-1/LFA-1 interaction using
mAbs, ICAM-1 or LFA-1 derived peptides as well as other small
molecule inhibitors51–53, leading to altered immune signalling to
control inflammatory and/or autoimmune responses. In case of
pathogenic infections, mAb against ICAM-1 as well as soluble
ICAM-1 (comprising only the ectodomain) have been previously
shown to block Human Rhinovirus infection54. While similar
blockade by antibodies was absent in case of Mtb, M5 is the first
such completely de novo protein binder that blocks Mtb entry to a
large extent into host cells.
ICAMs have also been implicated in malaria, although only
during the process of cytoadherence. P. falciparum-infected
erythrocytes sequester in deep vascular beds by binding to
ICAM-1 expressed on the surface of endothelial cells55. The
rationale behind examining the binding of M5 to ICAM-4 and
then to study whether it could also modulate P. falciparum
infection was threefold. First, all the Ig-like superfamily molecules
display a good degree of homology and bind common ligands.
ICAM-1 and ICAM-4 further share the ability to also bind
Mac-1 (refs 38,56,57). These interactions primarily elicit
immunologically important functions of cell adhesion and
inflammation. Second, P. falciparum-infected erythrocytes
express a protein PfEMP1 (a member of the ‘var’ antigen
family) that binds endothelial ICAM-1 and is responsible for the
manifestation of complicated cerebral malaria26. Finally, very
recently, another member of the Ig superfamily, Basigin, has been
characterized as a receptor for P. falciparum invasion of
erythrocytes15. Basigin is an RBC surface molecule expressed as
two isoforms; one isoform has two Ig-like domains (much like
ICAM-4) and the other isoform has three Ig-like domains.
Keeping the above-mentioned studies in mind, while analysing
our results in context of M5 to not only bind ICAM-1 but also
inhibit intracellular invasion of Mtb by virtue of its interaction,
we were curious to explore whether M5 could also bind other
ICAMs and elicit similar responses to other pathogens.
P. falciparum infection in RBCs provided a unique system for
this in that RBCs exclusively express ICAM-4 (and no other
ICAMs) on their cell surface. After confirming in vitro interaction
between M5 and ICAM-4, and proceeded with assessing its effect
on P. falciparum invasion.
A significant block (480%) in parasite invasion was observed
in the presence of M5 for both chloroquine-sensitive as well as
-resistant lines, suggesting a role of ICAM-4 as a receptor for
P. falciparum invasion of RBC. Further, M5 was able to block
invasion of both sialic acid-dependent as well as -independent
parasite lines. Invasion involves various events between receptors
on host RBCs and ligands on the merozoites, the invasive form of
the parasite. Microscopic analysis showed that the attachment of
merozoites to host blood cells was unaffected, indicating the role
of ICAM-4 at later stages of invasion post attachment. In
addition, purified recombinant ICAM-4 inhibited merozoite
invasion, possibly because recombinant ICAM-4 competed
directly with its membrane-bound homologue on the RBC
surface. Furthermore, recombinant purified ICAM-4 bound
released merozoites, thereby advocating the presence of ligand(s)
on the merozoite surface that interact with ICAM-4. Of the
various known receptor–ligand interactions, none except Basigin
has been shown to be essential across multiple P. falciparum
strains, suggesting redundant pathways for invasion. The
inhibition of erythrocyte invasion after addition of M5 by
multiple P. falciparum strains (3D7, Dd2, MCamp and HB3)
suggests that ICAM-4 is a critical host receptor marked for the
invasion process.
In summary, we describe here a systematic screen of an Mtb
genomic library with human host library leading to the
identification of ICAM-1 as a host-interacting protein. In
addition, we identify a completely de novo protein M5, unearthed
from a codon-shuffled peptide library, that acts as a potent binder
to ICAM-1 and ICAM-4. Using M5 and a well-known inhibitor
of ICAM-1 expression, A205804, as well as siRNA-based
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knockdown experiments, we further demonstrate ICAMs as
receptors essential for entry of two important intracellular
pathogens, namely, Mtb and P. falciparum into mammalian cells.
This study, we believe, provides two major outcomes. First, it
identifies two previously known adhesion molecules, ICAM-1
and ICAM-4, as possible receptors or accessory molecules
implicated in host cell invasion by Mtb and P. falciparum.
Modulating the two ICAMs provides a proof-of-concept to their
potential as new drug targets, with the synthetic polypeptide M5
presenting a template for designing lead peptidomimetic drug(s)
or small inhibitors against the two important intracellular
pathogens. Second, it also establishes an opportunity of utilizing
the described de novo peptide libraries to discover potent binders
of previously known drug targets/receptors for other pathogens.
Methods
Ethics statement. BALB/c female mice at 8 weeks of age were used for this study
following the institutional ethical committee guidelines. All animal experiments
were conducted in accordance with the guidelines approved by the Institutional
Animals Ethics Committee of ICGEB, New Delhi, India.
Human blood was used for P. falciparum culture in this study. Donor blood was
obtained from Rotary blood bank (RBB), New Delhi, India. RBB follows stringent
screening procedures, careful documentation and Good Laboratory Practices for
collecting, processing and testing blood and is an ISO 9001:2008 certified blood
bank established in 2002.
Mtb library construction. The Mtb H37Rv genomic library and the dicodon
library were constructed as described earlier29,33. Briefly, Mtb H37Rv genomic
DNA was isolated from bacteria grown in 7H9 broth supplemented with ADC
enrichment as described previously58 and subjected to partial digestion with HaeIII
and NlaI. The digested fragments varying from 200 bp to 2 kb in length were eluted
from a 1% agarose gel. Annealed phosphorylated (P) and PAGE-purified
double-stranded (ds) hairpin (see Supplementary Table 2) was ligated to eluted
genomic DNA fragments and the ligated products digested with XbaI. The ligated
DNA fragments were amplified using primers HP2P, bHP2P and cHP2P (see
Supplementary Table 2). These primers were designed such that they generated
phosphorylated 50 PCR-amplified fragments in three consecutive frames, which
were then cloned into SnaBI-digested and dephosphorylated pBTnn vector. The
library DNA was electroporated into XL-1 competent strains and plated on
chloramphenicol (30 mgml 1)-containing LB agar plates.
Dicodon library construction. Hundred nanograms of each of the fourteen28
P-50 DNA dicodons were taken in a 20-ml ligation reaction containing 7.5%
polyethylene glycol and gently heated to 55 C. The temperature was then slowly
brought down to 4 C. The DC mixture was incubated at 4 C for 24 h. To this
mixture were added 100 pmol of P-50 , PAGE-purified ds hairpins that had been
self-annealed earlier. The ligation temperature was increased to 16 C, and the
incubation prolonged for another 12 h. The DNA was precipitated from the
ligation mixture and extracted once with phenol/chloroform. The resuspended
DNA was digested with XbaI for 4 h at 37 C, after which 1 ml of the digested DNA
was used as a template for PCR using HP2P that served both as a forward and
reverse primer. The PCR products were eluted using DEAE membrane and
fractionated based on their lengths (50–400 bp). The purified fragments were
used directly as inserts for creation of de novo libraries in SnaBI-cut and
dephosphorylated pBTnn and pTRGnn vectors. The human lung cDNA library,
cloned into the pTRG vector, was acquired commercially from Stratagene,
CA, USA.
ICAM-1271 and M5 cloning. The 841-bp-long ICAM-1271 was divided into
separate domains, namely, extracellular (EC, 675 bp), transmembrane and
cytoplasmic (TMþCyto, 193 bp) and cytoplasmic tail (Cyto, 112 bp) and each
was cloned into SnaBI-cut and dephosphorylated pTRGnn and pBTnn vectors,
respectively. The inserts were PCR-amplified using the following primer sets:
ICAM-1271: ICAM-For, ICAM-Rev; ICAM-1EC: ICAM-For, ICAM-D3D5-Rev;
ICAM-1TMþCyto: ICAM-D3D5-For, ICAM-Rev and ICAM-1Cyto: ICAM-Cyto-
For, ICAM-Rev (see Supplementary Table 2).
The M5-encoding DNA sequence was PCR-amplified using HP2P primer and
used as an insert in a blunt-end cloning into SnaBI-cut and dephosphorylated
pMTSA vector33. The resulting plasmid was used for three-hybrid studies as well as
for expression of C-terminal His-tagged M5 protein.
Bacterial two-hybrid screen. The bacterial two-hybrid experiment was carried
out according to the protocol provided by the manufacturer (Stratagene). Briefly,
plasmids pBTnn, containing Mtb genomic DNA, and pTRGnn, containing human
lung cDNA were used to co-transform R1 reporter cells. The co-transformants
were plated on X-Gal indicator plates containing kanamycin (50 mgml 1),
chloramphenicol (30 mgml 1), tetracycline (12.5mgml 1), X-Gal (80mgml 1),
Isopropyl b-D-1-thiogalactopyranoside (25 mM) and phenylethyl-b-D-thioga-
lactoside (200 mM). Visual blue–white selection on the indicator plates was the
initial criteria for screening of colonies. Mycobacterial proteins CFP10 and ESAT6,
that are known to form a tight 1:1 complex32 and have been shown previously to
interact using a bacterial two-hybrid system33, were cloned into pBTnn and
pTRGnn, respectively, and used as positive controls. To discover interacting
de novo peptide/polypeptide/protein partners to known proteins, the bacterial two-
hybrid experiments between ICAM-1271pTRGnn and dicodon libraries cloned in
pBTnn were performed as described above. All interacting pairs thus found were
retransformed repeatedly, segregated and re-cloned to confirm the interactions.
Liquid b-galactosidase assays. To confirm and quantify the strength of protein–
protein interactions, the expression level of reporter enzyme b-galactosidase was
compared with the positive control in a colorimetric enzymatic assay59. To
ascertain statistical significance, a Student’s t-test was used to compare all values to
the negative control. Values of Po0.01 were considered as significant.
Bacterial three-hybrid screen. ICAM-1271 and its various fragments (Fig. 2)
cloned in both pBTnn and pTRGnn were used to set up bacterial two-hybrid
screens. All co-transformants were analysed for the presence of both plasmids
by PCR using vector-specific primers. ICAM-1271pBTnn/ICAM-1271pTRGnn,
ICAM-1ECpBTnn/ICAM-1ECpTRGnn and ICAM-1TMþCytopBTnn/ICAM-
1TMþCytopTRGnn interactions displayed blue colour, while ICAM-1CytopBTnn/
ICAM-1CytopTRGnn interaction yielded white colonies. The cells containing
the co-transformants were used to make competent cells, which were further
transformed with M5pMTSA and plated on X-Gal indicator plates, both in the
presence and absence of L-arabinose (1% w/v). The competent cells carrying the
two plasmids with ICAM-1Cyto (that yielded white colonies) and transformed with
M5pMTSA were treated as negative control. Transforming ICAM-1271 carrying
competent cells with empty pMTSA served as a vector control. The plates were
incubated at 30 C and reversion of colony colour from blue to white—upon
induction of M5 expression by L-arabinose—indicated disruption of ICAM-1
dimerization. The basis and validation of the bacterial three-hybrid system has
been described previously33.
Arabinose gradient liquid b-galactosidase assay. A liquid b-galactosidase assay,
but with increasing concentrations of L-Arabinose (0.0, 0.005, 0.01, 0.05, 0.1, 0.5,
1.0, 1.5 and 2.0mM), was carried out in triplicates as described previously33. To
ascertain statistical significance, a Student’s t-test was used to compare all values to
the negative control. Values of Po0.01 were considered as significant. E. coli BL21
(DE3) strain harbouring M5 cloned into pMTSA vector33 was induced with
corresponding concentrations (0.0–2.0mM as used in liquid b-galactosidase assay)
of L-arabinose, and whole-cell lysates of 5ml cultures were analysed by western
blot analysis for the expression of M5-His using anti-His antibody (anti-His mAb,
1mgml 1, 1:3,000 dilution).
Expression and purification of recombinant M5. To functionally characterize
M5-His, the 11-kDa C-terminal His-tagged polypeptide was overexpressed in a
heterologous E. coli expression system through arabinose induction. The expressed
protein was found in inclusion bodies. BL21 (DE3) cells carrying M5pMTSA
plasmid were inoculated in liquid culture media and grown overnight at 37 C in
the presence of streptomycin (50mgml 1). After growing the culture to mid-log
phase, it was induced with 0.2% L-arabinose at 25 C for 12 h. The culture was
pelleted and washed with 1 PBS and the cell pellet resuspended in lysis buffer
(1 PBS containing 2mM phenylmethylsulphonyl fluoride) and sonicated till a
clear lysate was obtained. The pellet fraction was resuspended in a buffer con-
taining 25mM Tris-HCl, 0.3M NaCl and 8M urea, and the proteins were extracted
using centrifugation. The resultant supernatant was bound to Ni-NTA superflow
resin at room temperature. The bound proteins were eluted from Ni-NTA through
an imidazole gradient between buffer A (8M urea, 25mM Tris-HCl, 0.3M NaCl,
20mM Imidazole, pH 8.5) and buffer B (8M urea, 25mM Tris-HCl, 0.3M NaCl,
500mM Imidazole, pH 8.5). The purification was performed using an FPLC system
(AKTA purifier, GE, USA). The pooled eluant was dialysed against 25mM Tris-
HCl, 0.3M buffer, pH 8.5, by step-dialysis to achieve gradual removal of urea from
8 to 0M. The protein was analysed on a Tris-Tricine PAGE and confirmed using
western blot using anti-His antibody (Sigma Aldrich, USA; Fig. 3a). The fractions
containing 490% of the recombinant protein were pooled and step-dialysed
against decreasing urea concentrations until the denaturant had been completely
removed. The purified protein was analysed on Tris-Tricine PAGE and was found
to be 490% pure. CD spectroscopy suggested M5 to be composed of B50%
b-sheets (Supplementary Fig. 3b). The secondary structure spectral analysis was
carried out using the K2d3 server (http://k2d3.ogic.ca)60.
In vitro protein interaction assays. Recombinant ICAM-1 (Cat. no. 10346-
HCCH-100) and recombinant ICAM-4 (Cat. no. 13327-H02H-100) were acquired
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from Sino Biological, China. Interactions between M5-His and recombinant
ICAMs were ascertained by various in vitro protein techniques described below.
In vitro protein pull-down. M5-His (10mg) was bound to the Ni-NTA resin. Beads
were washed twice with wash buffer I (25mM Tris-HCl, 0.3M NaCl, pH 8.5), and
once with wash buffer II (1PBS, 0.1% Tween-20, 14mM b-ME). Beads were then
blocked with 1% polyvinylpyrrolidone for 1 h. Following this, 10 mg of ICAM-1 was
added and the constituents incubated at room temperature for 2 h. In a control
experiment, Ni-NTA beads were blocked with 1% polyvinylpyrrolidone and
incubated with 10mg of ICAM-1 protein at room temperature for 2 h. Finally,
beads were washed extensively with wash buffer I. Resin-bound proteins were
eluted by boiling beads in 5 SDS-loading dye and analysed by 15% SDS–PAGE.
ELISA-based protein interaction. ELISA-based detection of in vitro protein–
protein interaction was carried out as reported earlier, with slight modifications in
the protocol61. Briefly, purified proteins were coated on a 96-well ELISA plate
(NuncMaxisorb ELISA plates) at varying concentrations (25, 50, 75 and 100 ng) in
0.1M carbonate/bicarbonate-coating buffer, pH 9.6. The protein-coated plates were
blocked with blocking buffer containing 1PBS, 0.1% Tween-20 and 1% BSA, at
room temperature for 2 h. Subsequently, the plates were washed three times with
PBST (1 PBS, 0.1% Tween-20). The washed plates were incubated with a 1:1 ratio
of the interacting protein partner in dilution buffer (1 PBST containing 0.5%
BSA), for 1 h at room temperature. Only the test wells were incubated with the
interacting protein partner while the control wells were incubated with a
noninteracting protein. Following washing, primary antibody (anti-his mAb—
1mgml 1, 1:3,000 dilution; anti-ICAM-1 pAb—200mgml 1, 1:500 dilution;
anti-ICAM-4 pAb—200 mgml 1, 1:500 dilution, see Supplementary Table 1)
against the overlaid protein was added to corresponding test and control wells and
incubated for 1 h at room temperature with gentle shaking. The horseradish
peroxidase-conjugated 2 antibody (0.8mgml 1, 1:5,000 dilution) was added to
the washed plates and samples incubated at room temperature for 1 h with gentle
shaking. The ELISA plates were thoroughly washed again, followed by addition of
soluble TMB substrate. The plates were incubated at 37 C for 30min and the
reaction stopped by addition of 1N H2SO4. Absorbance was measured at 450 nm
using a plate reader.
Surface plasmon resonance. SPR assays were performed on BIACORE 2000
instrument (GE Healthcare) at 37 C, using HBS-EP buffer (general purpose buffer,
degassed and ready to use 0.01M HEPES pH 7.4, 0.15M NaCl, 3mM EDTA,
0.005% v/v Surfactant P20; GE Healthcare). M5-His was immobilized up to 50
response units in a flow cell of CM5 sensor-chip (GE Healthcare). For kinetic
measurements, increasing concentrations of recombinant ICAM-4 were injected
over immobilized M5-His as well as the reference flow cell, at a flow rate of
20ml min 1. The surfaces were regenerated with a pulse of 10mM Glycine at pH
1.5 at the end of each injection cycle. Duplicate injections of the same con-
centration in each experiment were superimposable, demonstrating no loss of
activity after surface regeneration. Reference-subtracted sensorgrams were analysed
using the Biacore evaluation software 4.1.1 (GE Healthcare). To determine the
kinetic parameters of the interaction, binding responses in the steady-state region
of the sensorgrams were plotted against analyte concentration and fitted to the
standard 1:1 (Langmuir) bimolecular interaction with simultaneous fitting of ka
and kd. Kinetic constants were calculated by nonlinear regression fitting to the
association and dissociation phases of the sensorgrams.
H37Rv infection of macrophages. THP-1 cells were propagated in RPMI-1640
medium with 2mM L-Glutamine (Gibco, Life Technologies) supplemented with
10% FBS, 50 mgml 1 cefotaxime (Amresco LLC, USA) and 0.250 mgml 1
amphotericin B (Amresco LLC; hereafter referred to as ‘complete media’). In all,
1 106 cells were seeded in a 12-well plate and activated with PMA. Forty-eight
hours later, cells were incubated overnight with complete media containing varying
amounts of M5-His, nonspecific protein (ARPC4-His, 10 mM), polyclonal anti-
ICAM-1 antibody (Santa Cruz Biotechnology, USA, Clone H-108) and ICAM-1
inhibitor A205804 {(4-[(4-Methylphenyl) thio]thieno [2,3-c]pyridine-2-carbox-
amide), (Tocris Bioscience, R&D Systems, UK)}, in triplicates along with
appropriate cell controls. The cells were infected with Mtb H37Rv-GFP (see
Supplementary Table 1) at an multiplicity of infection of 10 and incubated at 37 C
and 5% CO2 for 4 h after which the cells were scraped from the wells. The pelleted
cells were washed once with 1 PBS followed by a wash with FACS wash buffer
(1 PBS, 3% FBS). The cells were then incubated for 1 h with Alexa Fluor-
conjugated anti-ICAM-1mAb (Santa Cruz Biotechnology, Clone 15.2). Fixed cells
(4% paraformaldehyde) were subjected to flow cytometry analyses on the BD
FACSCanto II platform. Fluorescence signals were detected with both FL1
(excitation 488, filter 530/30) and FL4 (excitation 640, filter 660/20) channel and
analysed based on emission spectra.
Five 8-week-old female BALB/c mice were administered 2ml of thioglycollate
through the intraperitoneal route. On the fifth day, mice were killed and immune
cells recovered by lavage of the peritoneal cavity. Enrichment of macrophages was
carried out by allowing them to settle and attach to the surface of assay wells in the
presence of complete media lasting 24 h. Mtb H37Rv-GFP infection assays in the
presence of M5 or A205804 inhibitor were performed as described above.
ICAM-1 siRNA transfection. Pre-validated and inventoried Silencer Select siRNAs
against ICAM-1 (Ambion, Life Technologies, see Supplementary Table 2) were
used to transfect PMA-activated THP-1 cells. Transfections were carried out with
DharmaFECT 2 transfection reagent (Dharmacon, GE Lifesciences) following the
manufacturer’s protocol. Briefly, 0.5 106 THP-1 cells were seeded in 12-well
plates in complete media in the presence of PMA to trigger activation. Following a
media change, the cells were allowed to rest for 24 h. ICAM-1 or scrambled siRNA
(60 nM) was used to transfect THP-1 in antibiotic-free RPMI-1640 containing 10%
FBS. Silencing of ICAM-1 expression following transfections was monitored at 48
and 72 h by western blot and flow cytometry analyses. The western blots were
probed with primary antibodies (anti-ICAM-1 pAb, 200 mgml 1, 1:500 dilution;
anti-GAPDH, 1mgml 1, 1:5,000 dilution) followed by washing. The blots were
incubated with secondary antibody (IRDye 800CW-conjugated, 1mgml 1,
1:15,000 dilution, LI-COR Inc., USA, see Supplementary Table 1) for an hour and
the signal detected on a LI-COR Odyssey CLx Infrared Imaging System. Maximum
silencing was observed at 72 h, at which time point Mtb H37Rv-GFP infection
assays were performed as described above.
Parasite culture. In vitro P. falciparum cultures were maintained following
standard protocols reported in ref. 62. Briefly, the parasite was cultured in Oþ
human erythrocytes in RPMI-1640 medium (Invitrogen) supplemented with 0.5%
AlbumaxII, 0.005% (w/v) hypoxanthine, 0.02% (w/v) sodium bicarbonate and
10 mgml 1 gentamycin at 37 C. The parasite cultures were synchronized by
sorbitol treatment as reported earlier63.
Staining of receptors and co-localization. Human erythrocytes were fixed with
1% paraformaldehyde for 1 h at room temperature (RT). They were washed with
1PBS followed by blocking in 3% BSA in 1PBS containing 0.2% Tween for
30min, following which the cells were incubated with anti-ICAM-4 pAb
(200 mgml 1, 1:200 dilution) in blocking buffer for 1 h at RT. The cells were
washed three times with 1 PBS containing 0.2% Tween-20 followed by
incubation with appropriate fluorochrome-conjugated secondary antibody
(2mgml 1, 1:1,500 dilution) for 1 h at RT. After washing, the samples were
analysed under Nikon A1 confocal microscope.
Human erythrocytes were incubated with 25 mM M5 for 1 h. Cells were cross-
linked with 50mM dimethyl suberimidate dihydrochloride in 100mM sodium
borate buffer (pH 9.5) containing 1mM MgCl2 for 1 h followed by fixing with 1%
paraformaldehyde for 1 h at RT. The reaction was quenched with 0.1M glycine in
1PBS, pH 7.4 for 1 h at RT. The cells were washed with PBS followed by blocking
with 3% BSA in 1PBS containing 0.2% Tween for 30min. Cells were incubated
with anti-ICAM-4 pAb and anti-His mAb (1mgml 1, 1:1,500) in blocking buffer
for 1 h at RT. The cells were washed three times with 1PBS containing 0.2%
Tween-20 followed by incubation with appropriate fluorochrome-conjugated
secondary antibodies (2mgml 1, 1:1,500 dilution, see Supplementary Table 1) for
1 h at RT. After washing, the samples were analysed under Nikon A1 confocal
microscope. For the antibody-masking experiments, the same protocol was
followed but with erythrocytes incubated with anti-ICAM-4 pAb (Santa Cruz
Biotechnology, Clone C-20) before addition of M5.
THP-1 macrophages were stained similarly, both for surface expression of
ICAM-1 as well as co-localization, with the slight modification that macrophages
were fixed after incubation with the fluorescent-conjugated secondary antibodies.
Invasion inhibition assay. The effect of M5 on parasite invasion was evaluated on
four different strains of P. falciparum (3D7, Dd2, HB3 and MCamp; see
Supplementary Table 1). Invasion inhibition assay was performed as described
previously64. Briefly, the haematocrit and parasitaemia of synchronized schizont
stage cultures was adjusted to 2% and 1%, respectively. M5 protein (7.5–25 mM)
was added to the parasite culture in 96-well plates and parasitaemia estimated after
an incubation of 24 h using flow cytometry. Briefly, cells from samples were
collected and washed twice with PBS followed by staining with ethidium bromide
(10 mgml 1) for 30min at room temperature in the dark. The cells were
subsequently washed twice with PBS and analysed on FACSCalibur (Becton
Dickinson) using the CellQuest software. Fluorescence signal (FL2) was detected
with the 590-nm band pass filter using an excitation laser of 488 nm collecting
100,000 cells per sample. Uninfected RBCs stained in similar manner were used as
background. Following acquisition, data were analysed for % parasitaemia of each
sample by determining the proportion of FL2-positive cells using CellQuest.
The data represent an average of three independent experiments conducted in
duplicate.
Merozoite invasion inhibition—staining for microscopy. Synchronized
P. falciparum culture containing schizonts was percoll-purified. The schizont-
enriched culture was grown for 6 h in complete RPMI-1640 medium containing
25 mM purified recombinant M5 protein at 2% haematocrit and 10% parasitaemia
in a 12-well plate. The cells were harvested by centrifugation at 4,000 g.
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Thin smears were made on glass slides followed by methanol fixation and staining
with Giemsa or DAPI. Giemsa-stained slides were analysed on Zeiss AxioCam ERc
5s microscope and DAPI-stained slides on Nikon A1 confocal microscope.
Merozoite staining. Synchronized P. falciparum culture containing schizonts was
percoll-purified. The schizont-enriched culture was grown for 8-10 h in complete
RPMI-1640 medium containing purified recombinant ICAM-4 protein. Released
merozoites having bound ICAM-4 protein were harvested by centrifugation at
3,300 g for 5min. The merozoites were fixed with 1% paraformaldehyde for 1 h
at RT, followed by blocking with 3% BSA in PBS for 30min at RT. After washing
with PBS, the merozoites were incubated with anti-ICAM-4 antibody for 1 h at RT
followed by incubation with secondary antibody for 1 h at RT. The merozoites were
washed and captured on lysine-coated slides followed by analysis under Nikon A1
confocal microscope.
Parasite growth inhibition assays. To rule out any inhibitory effect of M5 on
parasite developmental stages, we assessed the parasite developmental stage profile
in the presence of M5 protein. Early ring-stage parasites were incubated with M5
protein (15 mM) and allowed to grow through different developmental stages. For
microscopic analysis, smears were made from each well at different time points
(10, 20, 24, 30, 36, 48 and 52 hpi), fixed and subsequently stained with Giemsa, and
the number of parasites at different developmental stages counted.
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